{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:26:39Z","timestamp":1792639599773,"version":"4.5.0"},"reference-count":169,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T00:00:00Z","timestamp":1495152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2017,5,19]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>This is a review of the preclinical efficacy testing of new antituberculosis drug candidates. It describes existing dynamic<jats:italic>in vitro<\/jats:italic>and<jats:italic>in vivo<\/jats:italic>models of antituberculosis chemotherapy and their utility in preclinical evaluations of promising new drugs and combination regimens, with an effort to highlight recent developments. Emphasis is given to the integration of quantitative pharmacokinetic\/pharmacodynamic analyses and the impact of lesion pathology on drug efficacy. Discussion also includes<jats:italic>in vivo<\/jats:italic>models of chemotherapy of latent tuberculosis infection.<\/jats:p>","DOI":"10.1128\/microbiolspec.tbtb2-0034-2017","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T12:45:19Z","timestamp":1498221919000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":60,"title":["Preclinical Efficacy Testing of New Drug Candidates"],"prefix":"10.1128","volume":"5","author":[{"given":"Eric L.","family":"Nuermberger","sequence":"first","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, and Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231-1002"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","unstructured":"World Health Organization. 2016. Global tuberculosis report 2016. http:\/\/www.who.int\/tb\/publications\/global_report\/en\/."},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","unstructured":"Cegielski JP Dalton T Yagui M Wattanaamornkiet W Volchenkov GV Via LE Van Der Walt M Tupasi T Smith SE Odendaal R Leimane V Kvasnovsky C Kuznetsova T Kurbatova E Kummik T Kuksa L Kliiman K Kiryanova EV Kim H Kim CK Kazennyy BY Jou R Huang WL Ershova J Erokhin VV Diem L Contreras C Cho SN Chernousova LN Chen MP Caoili JC Bayona J Akksilp S Global Preserving Effective TB Treatment Study (PETTS) Investigators. 2014. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 59: 1049\u20131063 http:\/\/dx.doi.org\/10.1093\/cid\/ciu572.","DOI":"10.1093\/cid\/ciu572"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","unstructured":"Cegielski JP Kurbatova E van der Walt M Brand J Ershova J Tupasi T Caoili JC Dalton T Contreras C Yagui M Bayona J Kvasnovsky C Leimane V Kuksa L Chen MP Via LE Hwang SH Wolfgang M Volchenkov GV Somova T Smith SE Akksilp S Wattanaamornkiet W Kim HJ Kim CK Kazennyy BY Khorosheva T Kliiman K Viiklepp P Jou R Huang AS Vasilyeva IA Demikhova OV Global PETTS Investigators. 2016. Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Clin Infect Dis 62: 418\u2013430. [PubMed]","DOI":"10.1093\/cid\/civ910"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","unstructured":"Diacon AH Pym A Grobusch MP de los Rios JM Gotuzzo E Vasilyeva I Leimane V Andries K Bakare N De Marez T Haxaire-Theeuwes M Lounis N Meyvisch P De Paepe E van Heeswijk RP Dannemann B TMC207-C208 Study Group. 2014. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371: 723\u2013732 http:\/\/dx.doi.org\/10.1056\/NEJMoa1313865.","DOI":"10.1056\/NEJMoa1313865"},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","unstructured":"Lienhardt C L\u00f6nnroth K Menzies D Balasegaram M Chakaya J Cobelens F Cohn J Denkinger CM Evans TG K\u00e4llenius G Kaplan G Kumar AM Matthiessen L Mgone CS Mizrahi V Mukadi YD Nguyen VN Nordstr\u00f6m A Sizemore CF Spigelman M Squire SB Swaminathan S Van Helden PD Zumla A Weyer K Weil D Raviglione M. 2016. Translational research for tuberculosis elimination: priorities challenges and actions. PLoS Med 13: e1001965 http:\/\/dx.doi.org\/10.1371\/journal.pmed.1001965.","DOI":"10.1371\/journal.pmed.1001965"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","unstructured":"Grosset J. 1980. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med 1: 231\u2013241. [PubMed]","DOI":"10.1016\/S0272-5231(21)00072-1"},{"key":"e_1_3_1_8_2","unstructured":"Mitchison DA. 2000. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 4: 796\u2013806. [PubMed]"},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","unstructured":"Warner DF Mizrahi V. 2006. Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy. Clin Microbiol Rev 19: 558\u2013570 http:\/\/dx.doi.org\/10.1128\/CMR.00060-05.","DOI":"10.1128\/CMR.00060-05"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","unstructured":"Torrey HL Keren I Via LE Lee JS Lewis K. 2016. High persister mutants in Mycobacterium tuberculosis . PLoS One 11: e0155127 http:\/\/dx.doi.org\/10.1371\/journal.pone.0155127.","DOI":"10.1371\/journal.pone.0155127"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","unstructured":"Dorman SE Savic RM Goldberg S Stout JE Schluger N Muzanyi G Johnson JL Nahid P Hecker EJ Heilig CM Bozeman L Feng PJ Moro RN MacKenzie W Dooley KE Nuermberger EL Vernon A Weiner M Tuberculosis Trials Consortium. 2015. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized dose-ranging trial. Am J Respir Crit Care Med 191: 333\u2013343 http:\/\/dx.doi.org\/10.1164\/rccm.201410-1843OC.","DOI":"10.1164\/rccm.201410-1843OC"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","unstructured":"Boeree MJ Heinrich N Aarnoutse R Diacon AH Dawson R Rehal S Kibiki GS Churchyard G Sanne I Ntinginya NE Minja LT Hunt RD Charalambous S Hanekom M Semvua HH Mpagama SG Manyama C Mtafya B Reither K Wallis RS Venter A Narunsky K Mekota A Henne S Colbers A van Balen GP Gillespie SH Phillips PP Hoelscher M PanACEA consortium. 2017. High-dose rifampicin moxifloxacin and SQ109 for treating tuberculosis: a multi-arm multi-stage randomised controlled trial. Lancet Infect Dis 17: 39\u201349 http:\/\/dx.doi.org\/10.1016\/S1473-3099(16)30274-2.","DOI":"10.1016\/S1473-3099(16)30274-2"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","unstructured":"Warner DF Mizrahi V. 2014. Shortening treatment for tuberculosis: to basics. N Engl J Med 371: 1642\u20131643 http:\/\/dx.doi.org\/10.1056\/NEJMe1410977.","DOI":"10.1056\/NEJMe1410977"},{"key":"e_1_3_1_14_2","unstructured":"Bartelink IH Zhang N Keizer RJ Strydom N Converse PJ Dooley KE Nuermberger EL Savic RM. A new paradigm for translational modeling to predict long-term tuberculosis treatment response. Clin Transl Sci . In press."},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","unstructured":"Lanoix JP Chaisson RE Nuermberger EL. 2016. Shortening tuberculosis treatment with fluoroquinolones: lost in translation? Clin Infect Dis 62: 484\u2013490. [PubMed]","DOI":"10.1093\/cid\/civ911"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","unstructured":"Nuermberger E Sizemore C Romero K Hanna D. 2016. Toward an evidence-based nonclinical road map for evaluating the efficacy of new tuberculosis (TB) drug regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development. Antimicrob Agents Chemother 60: 1177\u20131182 http:\/\/dx.doi.org\/10.1128\/AAC.02041-15.","DOI":"10.1128\/AAC.02041-15"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","unstructured":"Gumbo T Lenaerts AJ Hanna D Romero K Nuermberger E. 2015. Nonclinical models for antituberculosis drug development: a landscape analysis. J Infect Dis 211 (Suppl 3) : S83\u2013S95 http:\/\/dx.doi.org\/10.1093\/infdis\/jiv183.","DOI":"10.1093\/infdis\/jiv183"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","unstructured":"Dartois V. 2014. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol 12: 159\u2013167 http:\/\/dx.doi.org\/10.1038\/nrmicro3200.","DOI":"10.1038\/nrmicro3200"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","unstructured":"Gumbo T Angulo-Barturen I Ferrer-Bazaga S. 2015. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J Infect Dis 211 (Suppl 3) : S96\u2013S106 http:\/\/dx.doi.org\/10.1093\/infdis\/jiu610.","DOI":"10.1093\/infdis\/jiu610"},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","unstructured":"Gumbo T Louie A Liu W Brown D Ambrose PG Bhavnani SM Drusano GL. 2007. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 51: 2329\u20132336 http:\/\/dx.doi.org\/10.1128\/AAC.00185-07.","DOI":"10.1128\/AAC.00185-07"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"Dooley KE Mitnick CD DeGroote MA Obuku E Belitsky V Hamilton CD Makhene M Shah S Brust JC Durakovic N Nuermberger E Efficacy Subgroup RESIST-TB. 2012. Old drugs new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clin Infect Dis 55: 572\u2013581 http:\/\/dx.doi.org\/10.1093\/cid\/cis487","DOI":"10.1093\/cid\/cis487"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","unstructured":"Gumbo T Siyambalapitiyage Dona CSW Meek C Leff R. 2009. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 53: 3197\u20133204 http:\/\/dx.doi.org\/10.1128\/AAC.01681-08.","DOI":"10.1128\/AAC.01681-08"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","unstructured":"Yew WW Nuermberger E. 2013. High-dose fluoroquinolones in short-course regimens for treatment of MDR-TB: the way forward? Int J Tuberc Lung Dis 17: 853\u2013854 http:\/\/dx.doi.org\/10.5588\/ijtld.13.0301.","DOI":"10.5588\/ijtld.13.0301"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","unstructured":"Gumbo T Louie A Deziel MR Parsons LM Salfinger M Drusano GL. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis by use of an i pharmacodynamic infection model and mathematical modeling. J Infect Dis 190: 1642\u20131651 http:\/\/dx.doi.org\/10.1086\/424849.","DOI":"10.1086\/424849"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","unstructured":"Srivastava S Modongo C Siyambalapitiyage Dona CW Pasipanodya JG Deshpande D Gumbo T. 2016. Amikacin optimal exposure targets in the hollow-fiber system model of tuberculosis. Antimicrob Agents Chemother 60: 5922\u20135927 http:\/\/dx.doi.org\/10.1128\/AAC.00961-16.","DOI":"10.1128\/AAC.00961-16"},{"key":"e_1_3_1_26_2","unstructured":"Peloquin C. 2003. What is the \u2018right\u2019 dose of rifampin? Int J Tuberc Lung Dis 7: 3\u20135. [PubMed]"},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","unstructured":"Pasipanodya JG Srivastava S Gumbo T. 2012. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 55: 169\u2013177 http:\/\/dx.doi.org\/10.1093\/cid\/cis353.","DOI":"10.1093\/cid\/cis353"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","unstructured":"Srivastava S Pasipanodya JG Meek C Leff R Gumbo T. 2011. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 204: 1951\u20131959 http:\/\/dx.doi.org\/10.1093\/infdis\/jir658.","DOI":"10.1093\/infdis\/jir658"},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","unstructured":"Gumbo T Louie A Liu W Ambrose PG Bhavnani SM Brown D Drusano GL. 2007. Isoniazid\u2019s bactericidal activity ceases because of the emergence of resistance not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 195: 194\u2013201 http:\/\/dx.doi.org\/10.1086\/510247.","DOI":"10.1086\/510247"},{"key":"e_1_3_1_30_2","doi-asserted-by":"crossref","unstructured":"Srivastava S Deshpande D Pasipanodya J Nuermberger E Swaminathan S Gumbo T. 2016. Optimal clinical doses of faropenem linezolid and moxifloxacin in children with disseminated tuberculosis: Goldilocks. Clin Infect Dis 63 (Suppl 3) : S102\u2013S109 http:\/\/dx.doi.org\/10.1093\/cid\/ciw483.","DOI":"10.1093\/cid\/ciw483"},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","unstructured":"Ahmad Z Peloquin CA Singh RP Derendorf H Tyagi S Ginsberg A Grosset JH Nuermberger EL. 2011. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 55: 239\u2013245 http:\/\/dx.doi.org\/10.1128\/AAC.00849-10.","DOI":"10.1128\/AAC.00849-10"},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","unstructured":"Jayaram R Gaonkar S Kaur P Suresh BL Mahesh BN Jayashree R Nandi V Bharat S Shandil RK Kantharaj E Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47: 2118\u20132124 http:\/\/dx.doi.org\/10.1128\/AAC.47.7.2118-2124.2003.","DOI":"10.1128\/AAC.47.7.2118-2124.2003"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","unstructured":"Jayaram R Shandil RK Gaonkar S Kaur P Suresh BL Mahesh BN Jayashree R Nandi V Bharath S Kantharaj E Balasubramanian V. 2004. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 48: 2951\u20132957 http:\/\/dx.doi.org\/10.1128\/AAC.48.8.2951-2957.2004.","DOI":"10.1128\/AAC.48.8.2951-2957.2004"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","unstructured":"Brown AN Drusano GL Adams JR Rodriquez JL Jambunathan K Baluya DL Brown DL Kwara A Mirsalis JC Hafner R Louie A. 2015. Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy. MBio 6: e01741-15 http:\/\/dx.doi.org\/10.1128\/mBio.01741-15.","DOI":"10.1128\/mBio.01741-15"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","unstructured":"Irwin SM Prideaux B Lyon ER Zimmerman MD Brooks EJ Schrupp CA Chen C Reichlen MJ Asay BC Voskuil MI Nuermberger EL Andries K Lyons MA Dartois V Lenaerts AJ. 2016. Bedaquiline and pyrazinamide treatment responses are affected by pulmonary lesion heterogeneity in Mycobacterium tuberculosis infected C3HeB\/FeJ mice. ACS Infect Dis 2: 251\u2013267 http:\/\/dx.doi.org\/10.1021\/acsinfecdis.5b00127.","DOI":"10.1021\/acsinfecdis.5b00127"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","unstructured":"Lanoix JP Ioerger T Ormond A Kaya F Sacchettini J Dartois V Nuermberger E. 2015. Selective inactivity of pyrazinamide against tuberculosis in C3HeB\/FeJ mice is best explained by neutral pH of caseum. Antimicrob Agents Chemother 60: 735\u2013743 http:\/\/dx.doi.org\/10.1128\/AAC.01370-15.","DOI":"10.1128\/AAC.01370-15"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","unstructured":"Franzblau SG DeGroote MA Cho SH Andries K Nuermberger E Orme IM Mdluli K Angulo-Barturen I Dick T Dartois V Lenaerts AJ. 2012. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis . Tuberculosis (Edinb) 92: 453\u2013488 http:\/\/dx.doi.org\/10.1016\/j.tube.2012.07.003.","DOI":"10.1016\/j.tube.2012.07.003"},{"key":"e_1_3_1_38_2","doi-asserted-by":"crossref","unstructured":"Craig WA. 1998. Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26: 1\u201310 quiz 11\u201312 http:\/\/dx.doi.org\/10.1086\/516284.","DOI":"10.1086\/516284"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","unstructured":"Ginsburg AS Lee J Woolwine SC Grosset JH Hamzeh FM Bishai WR. 2005. Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system. Antimicrob Agents Chemother 49: 853\u2013856 http:\/\/dx.doi.org\/10.1128\/AAC.49.2.853-856.2005.","DOI":"10.1128\/AAC.49.2.853-856.2005"},{"key":"e_1_3_1_40_2","doi-asserted-by":"crossref","unstructured":"Drusano GL Sgambati N Eichas A Brown DL Kulawy R Louie A. 2010. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. MBio 1: e00139-10. doi:10.1128\/mBio.00139-10.","DOI":"10.1128\/mBio.00139-10"},{"key":"e_1_3_1_41_2","doi-asserted-by":"crossref","unstructured":"Deshpande D Srivastava S Pasipanodya JG Bush SJ Nuermberger E Swaminathan S Gumbo T. 2016. Linezolid for infants and toddlers with disseminated tuberculosis: first steps. Clin Infect Dis 63 (Suppl 3) : S80\u2013S87 http:\/\/dx.doi.org\/10.1093\/cid\/ciw482.","DOI":"10.1093\/cid\/ciw482"},{"key":"e_1_3_1_42_2","doi-asserted-by":"crossref","unstructured":"Pasipanodya JG Nuermberger E Romero K Hanna D Gumbo T. 2015. Systematic analysis of hollow fiber model of tuberculosis experiments. Clin Infect Dis 61 (Suppl 1) : S10\u2013S17 http:\/\/dx.doi.org\/10.1093\/cid\/civ425.","DOI":"10.1093\/cid\/civ425"},{"key":"e_1_3_1_43_2","doi-asserted-by":"crossref","unstructured":"Rullas J Dhar N McKinney JD Garc\u00eda-P\u00e9rez A Lelievre J Diacon AH Hugonnet JE Arthur M Angulo-Barturen I Barros-Aguirre D Ballell L. 2015. Combinations of \u03b2-lactam antibiotics currently in clinical trials are efficacious in a DHP-I-deficient mouse model of tuberculosis infection. Antimicrob Agents Chemother 59: 4997\u20134999 http:\/\/dx.doi.org\/10.1128\/AAC.01063-15.","DOI":"10.1128\/AAC.01063-15"},{"key":"e_1_3_1_44_2","doi-asserted-by":"crossref","unstructured":"Gumbo T Pasipanodya JG Nuermberger E Romero K Hanna D. 2015. Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm. Clin Infect Dis 61 (Suppl 1) : S18\u2013S24 http:\/\/dx.doi.org\/10.1093\/cid\/civ426.","DOI":"10.1093\/cid\/civ426"},{"key":"e_1_3_1_45_2","doi-asserted-by":"crossref","unstructured":"Gumbo T Pasipanodya JG Romero K Hanna D Nuermberger E. 2015. Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes. Clin Infect Dis 61 (Suppl 1) : S25\u2013S31 http:\/\/dx.doi.org\/10.1093\/cid\/civ427.","DOI":"10.1093\/cid\/civ427"},{"key":"e_1_3_1_46_2","doi-asserted-by":"crossref","unstructured":"Gumbo T. 2010. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic\/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 54: 1484\u20131491 http:\/\/dx.doi.org\/10.1128\/AAC.01474-09.","DOI":"10.1128\/AAC.01474-09"},{"key":"e_1_3_1_47_2","doi-asserted-by":"crossref","unstructured":"Gumbo T Chigutsa E Pasipanodya J Visser M van Helden PD Sirgel FA McIlleron H. 2014. The pyrazinamide susceptibility breakpoint above which combination therapy fails. J Antimicrob Chemother 69: 2420\u20132425 http:\/\/dx.doi.org\/10.1093\/jac\/dku136.","DOI":"10.1093\/jac\/dku136"},{"key":"e_1_3_1_48_2","doi-asserted-by":"crossref","unstructured":"Chilukuri D McMaster O Bergman K Colangelo P Snow K Toerner JG. 2015. The hollow fiber system model in the nonclinical evaluation of antituberculosis drug regimens. Clin Infect Dis 61 (Suppl 1) : S32\u2013S33 http:\/\/dx.doi.org\/10.1093\/cid\/civ460.","DOI":"10.1093\/cid\/civ460"},{"key":"e_1_3_1_49_2","doi-asserted-by":"crossref","unstructured":"Cavaleri M Manolis E. 2015. Hollow fiber system model for tuberculosis: the European Medicines Agency experience. Clin Infect Dis 61 (Suppl 1) : S1\u2013S4 http:\/\/dx.doi.org\/10.1093\/cid\/civ484.","DOI":"10.1093\/cid\/civ484"},{"key":"e_1_3_1_50_2","unstructured":"European Medicines Agency. 2015. Final qualification opinion. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2015\/02\/WC500181899.pdf."},{"key":"e_1_3_1_51_2","doi-asserted-by":"crossref","unstructured":"Canetti G. 1955. The Tubercle Bacillus in the Pulmonary Lesion of Man . Springer New York NY.","DOI":"10.1097\/00000441-195604000-00012"},{"key":"e_1_3_1_52_2","doi-asserted-by":"crossref","unstructured":"Hoff DR Ryan GJ Driver ER Ssemakulu CC De Groote MA Basaraba RJ Lenaerts AJ. 2011. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS One 6: e17550 http:\/\/dx.doi.org\/10.1371\/journal.pone.0017550.","DOI":"10.1371\/journal.pone.0017550"},{"key":"e_1_3_1_53_2","doi-asserted-by":"crossref","unstructured":"Irwin SM Driver E Lyon E Schrupp C Ryan G Gonzalez-Juarrero M Basaraba RJ Nuermberger EL Lenaerts AJ. 2015. Presence of multiple lesion types with vastly different microenvironments in C3HeB\/FeJ mice following aerosol infection with Mycobacterium tuberculosis . Dis Model Mech 8: 591\u2013602 http:\/\/dx.doi.org\/10.1242\/dmm.019570.","DOI":"10.1242\/dmm.019570"},{"key":"e_1_3_1_54_2","doi-asserted-by":"crossref","unstructured":"Lanoix JP Lenaerts AJ Nuermberger EL. 2015. Heterogeneous disease progression and treatment response in a C3HeB\/FeJ mouse model of tuberculosis. Dis Model Mech 8: 603\u2013610 http:\/\/dx.doi.org\/10.1242\/dmm.019513.","DOI":"10.1242\/dmm.019513"},{"key":"e_1_3_1_55_2","doi-asserted-by":"crossref","unstructured":"Hunter RL. 2011. Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis (Edinb) 91: 497\u2013509 http:\/\/dx.doi.org\/10.1016\/j.tube.2011.03.007.","DOI":"10.1016\/j.tube.2011.03.007"},{"key":"e_1_3_1_56_2","doi-asserted-by":"crossref","unstructured":"Mattila JT Ojo OO Kepka-Lenhart D Marino S Kim JH Eum SY Via LE Barry CE III Klein E Kirschner DE Morris SM Jr Lin PL Flynn JL. 2013. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol 191: 773\u2013784 http:\/\/dx.doi.org\/10.4049\/jimmunol.1300113.","DOI":"10.4049\/jimmunol.1300113"},{"key":"e_1_3_1_57_2","doi-asserted-by":"crossref","unstructured":"Lin PL Ford CB Coleman MT Myers AJ Gawande R Ioerger T Sacchettini J Fortune SM Flynn JL. 2014. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med 20: 75\u201379 http:\/\/dx.doi.org\/10.1038\/nm.3412.","DOI":"10.1038\/nm.3412"},{"key":"e_1_3_1_58_2","doi-asserted-by":"crossref","unstructured":"Kaplan G Post FA Moreira AL Wainwright H Kreiswirth BN Tanverdi M Mathema B Ramaswamy SV Walther G Steyn LM Barry CE III Bekker LG. 2003. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 71: 7099\u20137108 http:\/\/dx.doi.org\/10.1128\/IAI.71.12.7099-7108.2003.","DOI":"10.1128\/IAI.71.12.7099-7108.2003"},{"key":"e_1_3_1_59_2","doi-asserted-by":"crossref","unstructured":"Zhang Y Permar S Sun Z. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 51: 42\u201349 http:\/\/dx.doi.org\/10.1099\/0022-1317-51-1-42.","DOI":"10.1099\/0022-1317-51-1-42"},{"key":"e_1_3_1_60_2","doi-asserted-by":"crossref","unstructured":"Wayne LG Sramek HA. 1994. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis . Antimicrob Agents Chemother 38: 2054\u20132058 http:\/\/dx.doi.org\/10.1128\/AAC.38.9.2054.","DOI":"10.1128\/AAC.38.9.2054"},{"key":"e_1_3_1_61_2","doi-asserted-by":"crossref","unstructured":"Driver ER Ryan GJ Hoff DR Irwin SM Basaraba RJ Kramnik I Lenaerts AJ. 2012. Evaluation of a mouse model of necrotic granuloma formation using C3HeB\/FeJ mice for testing of drugs against Mycobacterium tuberculosis . Antimicrob Agents Chemother 56: 3181\u20133195 http:\/\/dx.doi.org\/10.1128\/AAC.00217-12.","DOI":"10.1128\/AAC.00217-12"},{"key":"e_1_3_1_62_2","doi-asserted-by":"crossref","unstructured":"Hoff DR Caraway ML Brooks EJ Driver ER Ryan GJ Peloquin CA Orme IM Basaraba RJ Lenaerts AJ. 2008. Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis . Antimicrob Agents Chemother 52: 4137\u20134140 http:\/\/dx.doi.org\/10.1128\/AAC.00196-08.","DOI":"10.1128\/AAC.00196-08"},{"key":"e_1_3_1_63_2","doi-asserted-by":"crossref","unstructured":"Lin PL Dartois V Johnston PJ Janssen C Via L Goodwin MB Klein E Barry CE III Flynn JL. 2012. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci USA 109: 14188\u201314193 http:\/\/dx.doi.org\/10.1073\/pnas.1121497109.","DOI":"10.1073\/pnas.1121497109"},{"key":"e_1_3_1_64_2","doi-asserted-by":"crossref","unstructured":"Via LE Lin PL Ray SM Carrillo J Allen SS Eum SY Taylor K Klein E Manjunatha U Gonzales J Lee EG Park SK Raleigh JA Cho SN McMurray DN Flynn JL Barry CE III. 2008. Tuberculous granulomas are hypoxic in guinea pigs rabbits and nonhuman primates. Infect Immun 76: 2333\u20132340 http:\/\/dx.doi.org\/10.1128\/IAI.01515-07.","DOI":"10.1128\/IAI.01515-07"},{"key":"e_1_3_1_65_2","doi-asserted-by":"crossref","unstructured":"Kjellsson MC Via LE Goh A Weiner D Low KM Kern S Pillai G Barry CE III Dartois V. 2012. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother 56: 446\u2013457 http:\/\/dx.doi.org\/10.1128\/AAC.05208-11.","DOI":"10.1128\/AAC.05208-11"},{"key":"e_1_3_1_66_2","doi-asserted-by":"crossref","unstructured":"Prideaux B Via LE Zimmerman MD Eum S Sarathy J O\u2019Brien P Chen C Kaya F Weiner DM Chen PY Song T Lee M Shim TS Cho JS Kim W Cho SN Olivier KN Barry CE III Dartois V. 2015. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med 21: 1223\u20131227 http:\/\/dx.doi.org\/10.1038\/nm.3937.","DOI":"10.1038\/nm.3937"},{"key":"e_1_3_1_67_2","doi-asserted-by":"crossref","unstructured":"Nuermberger E. 2008. Using animal models to develop new treatments for tuberculosis. Semin Respir Crit Care Med 29: 542\u2013551 http:\/\/dx.doi.org\/10.1055\/s-0028-1085705.","DOI":"10.1055\/s-0028-1085705"},{"key":"e_1_3_1_68_2","doi-asserted-by":"crossref","unstructured":"Harper J Skerry C Davis SL Tasneen R Weir M Kramnik I Bishai WR Pomper MG Nuermberger EL Jain SK. 2012. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 205: 595\u2013602 http:\/\/dx.doi.org\/10.1093\/infdis\/jir786.","DOI":"10.1093\/infdis\/jir786"},{"key":"e_1_3_1_69_2","unstructured":"Dhillon J Allen BW Hu YM Coates AR Mitchison DA. 1998. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis 2: 736\u2013742. [PubMed]"},{"key":"e_1_3_1_70_2","doi-asserted-by":"crossref","unstructured":"Irwin SM Gruppo V Brooks E Gilliland J Scherman M Reichlen MJ Leistikow R Kramnik I Nuermberger EL Voskuil MI Lenaerts AJ. 2014. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother 58: 4026\u20134034 http:\/\/dx.doi.org\/10.1128\/AAC.02565-14.","DOI":"10.1128\/AAC.02565-14"},{"key":"e_1_3_1_71_2","doi-asserted-by":"crossref","unstructured":"Williams K Minkowski A Amoabeng O Peloquin CA Taylor D Andries K Wallis RS Mdluli KE Nuermberger EL. 2012. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56: 3114\u20133120 http:\/\/dx.doi.org\/10.1128\/AAC.00384-12.","DOI":"10.1128\/AAC.00384-12"},{"key":"e_1_3_1_72_2","unstructured":"Grosset J. 1978. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 53: 5\u201312."},{"key":"e_1_3_1_73_2","doi-asserted-by":"crossref","unstructured":"Gillespie SH Crook AM McHugh TD Mendel CM Meredith SK Murray SR Pappas F Phillips PP Nunn AJ REMoxTB Consortium. 2014. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371: 1577\u20131587 http:\/\/dx.doi.org\/10.1056\/NEJMoa1407426.","DOI":"10.1056\/NEJMoa1407426"},{"key":"e_1_3_1_74_2","doi-asserted-by":"crossref","unstructured":"Nuermberger EL Yoshimatsu T Tyagi S O\u2019Brien RJ Vernon AN Chaisson RE Bishai WR Grosset JH. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169: 421\u2013426 http:\/\/dx.doi.org\/10.1164\/rccm.200310-1380OC.","DOI":"10.1164\/rccm.200310-1380OC"},{"key":"e_1_3_1_75_2","doi-asserted-by":"crossref","unstructured":"Nuermberger EL Yoshimatsu T Tyagi S Williams K Rosenthal I O\u2019Brien RJ Vernon AA Chaisson RE Bishai WR Grosset JH. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170: 1131\u20131134 http:\/\/dx.doi.org\/10.1164\/rccm.200407-885OC.","DOI":"10.1164\/rccm.200407-885OC"},{"key":"e_1_3_1_76_2","doi-asserted-by":"crossref","unstructured":"Nuermberger E Tyagi S Tasneen R Williams KN Almeida D Rosenthal I Grosset JH. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824 moxifloxacin and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52: 1522\u20131524 http:\/\/dx.doi.org\/10.1128\/AAC.00074-08.","DOI":"10.1128\/AAC.00074-08"},{"key":"e_1_3_1_77_2","doi-asserted-by":"crossref","unstructured":"Tasneen R Betoudji F Tyagi S Li SY Williams K Converse PJ Dartois V Yang T Mendel CM Mdluli KE Nuermberger EL. 2015. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother 60: 270\u2013277 http:\/\/dx.doi.org\/10.1128\/AAC.01691-15.","DOI":"10.1128\/AAC.01691-15"},{"key":"e_1_3_1_78_2","doi-asserted-by":"crossref","unstructured":"Tasneen R Li SY Peloquin CA Taylor D Williams KN Andries K Mdluli KE Nuermberger EL. 2011. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 55: 5485\u20135492 http:\/\/dx.doi.org\/10.1128\/AAC.05293-11.","DOI":"10.1128\/AAC.05293-11"},{"key":"e_1_3_1_79_2","doi-asserted-by":"crossref","unstructured":"Tasneen R Williams K Amoabeng O Minkowski A Mdluli KE Upton AM Nuermberger EL. 2015. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother 59: 129\u2013135 http:\/\/dx.doi.org\/10.1128\/AAC.03822-14.","DOI":"10.1128\/AAC.03822-14"},{"key":"e_1_3_1_80_2","doi-asserted-by":"crossref","unstructured":"Dawson R Diacon AH Everitt D van Niekerk C Donald PR Burger DA Schall R Spigelman M Conradie A Eisenach K Venter A Ive P Page-Shipp L Variava E Reither K Ntinginya NE Pym A von Groote-Bidlingmaier F Mendel CM. 2015. Efficiency and safety of the combination of moxifloxacin pretomanid (PA-824) and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b open-label partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 385: 1738\u20131747 http:\/\/dx.doi.org\/10.1016\/S0140-6736(14)62002-X.","DOI":"10.1016\/S0140-6736(14)62002-X"},{"key":"e_1_3_1_81_2","doi-asserted-by":"crossref","unstructured":"Diacon AH Dawson R von Groote-Bidlingmaier F Symons G Venter A Donald PR van Niekerk C Everitt D Hutchings J Burger DA Schall R Mendel CM. 2015. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 191: 943\u2013953 http:\/\/dx.doi.org\/10.1164\/rccm.201410-1801OC.","DOI":"10.1164\/rccm.201410-1801OC"},{"key":"e_1_3_1_82_2","doi-asserted-by":"crossref","unstructured":"Diacon AH Dawson R von Groote-Bidlingmaier F Symons G Venter A Donald PR van Niekerk C Everitt D Winter H Becker P Mendel CM Spigelman MK. 2012. 14-day bactericidal activity of PA-824 bedaquiline pyrazinamide and moxifloxacin combinations: a randomised trial. Lancet 380: 986\u2013993 http:\/\/dx.doi.org\/10.1016\/S0140-6736(12)61080-0.","DOI":"10.1016\/S0140-6736(12)61080-0"},{"key":"e_1_3_1_83_2","doi-asserted-by":"crossref","unstructured":"Gill WP Harik NS Whiddon MR Liao RP Mittler JE Sherman DR. 2009. A replication clock for Mycobacterium tuberculosis . Nat Med 15: 211\u2013214 http:\/\/dx.doi.org\/10.1038\/nm.1915.","DOI":"10.1038\/nm.1915"},{"key":"e_1_3_1_84_2","doi-asserted-by":"crossref","unstructured":"Medina E North RJ. 1998. Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology 93: 270\u2013274 http:\/\/dx.doi.org\/10.1046\/j.1365-2567.1998.00419.x.","DOI":"10.1046\/j.1365-2567.1998.00419.x"},{"key":"e_1_3_1_85_2","doi-asserted-by":"crossref","unstructured":"Nuermberger EL. 2011. The role of the mouse model in the evaluation of new antituberculosis drugs p 145\u2013152. In Donald PR van Helden PD (ed) Antituberculosis Chemotherapy vol 40. Karger Basel Switzerland.","DOI":"10.1159\/000323633"},{"key":"e_1_3_1_86_2","doi-asserted-by":"crossref","unstructured":"Rullas J Garc\u00eda JI Beltr\u00e1n M Cardona PJ C\u00e1ceres N Garc\u00eda-Bustos JF Angulo-Barturen I. 2010. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob Agents Chemother 54: 2262\u20132264 http:\/\/dx.doi.org\/10.1128\/AAC.01423-09.","DOI":"10.1128\/AAC.01423-09"},{"key":"e_1_3_1_87_2","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-El\u00edas EJ Timm J Botha T Chan WT Gomez JE McKinney JD. 2005. Replication dynamics of Mycobacterium tuberculosis in chronically infected mice. Infect Immun 73: 546\u2013551 http:\/\/dx.doi.org\/10.1128\/IAI.73.1.546-551.2005.","DOI":"10.1128\/IAI.73.1.546-551.2005"},{"key":"e_1_3_1_88_2","unstructured":"Canetti G. 1965. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 92: 687\u2013703. [PubMed]"},{"key":"e_1_3_1_89_2","doi-asserted-by":"crossref","unstructured":"Grosset J Ji B. 1998. Experimental chemotherapy of mycobacterial diseases p 51\u201397. In Gangadharam PRJ Jenkins PA (ed) Mycobacteria vol II. Chapman & Hall New York NY. http:\/\/dx.doi.org\/10.1007\/978-1-4615-7511-5_3","DOI":"10.1007\/978-1-4615-7511-5_3"},{"key":"e_1_3_1_90_2","doi-asserted-by":"crossref","unstructured":"Pan H Yan BS Rojas M Shebzukhov YV Zhou H Kobzik L Higgins DE Daly MJ Bloom BR Kramnik I. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434: 767\u2013772 http:\/\/dx.doi.org\/10.1038\/nature03419.","DOI":"10.1038\/nature03419"},{"key":"e_1_3_1_91_2","doi-asserted-by":"crossref","unstructured":"Kramnik I Dietrich WF Demant P Bloom BR. 2000. Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis . Proc Natl Acad Sci USA 97: 8560\u20138565 http:\/\/dx.doi.org\/10.1073\/pnas.150227197.","DOI":"10.1073\/pnas.150227197"},{"key":"e_1_3_1_92_2","doi-asserted-by":"crossref","unstructured":"Pichugin AV Yan BS Sloutsky A Kobzik L Kramnik I. 2009. Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am J Pathol 174: 2190\u20132201 http:\/\/dx.doi.org\/10.2353\/ajpath.2009.081075.","DOI":"10.2353\/ajpath.2009.081075"},{"key":"e_1_3_1_93_2","doi-asserted-by":"crossref","unstructured":"Leu JS Chen ML Chang SY Yu SL Lin CW Wang H Chen WC Chang CH Wang JY Lee LN Yu CJ Kramnik I Yan BS. 2017. SP110b controls host immunity and susceptibility to tuberculosis. Am J Respir Crit Care Med 195: 369\u2013382. [PubMed]","DOI":"10.1164\/rccm.201601-0103OC"},{"key":"e_1_3_1_94_2","doi-asserted-by":"crossref","unstructured":"He X Berland R Mekasha S Christensen TG Alroy J Kramnik I Ingalls RR. 2013. The sst1 resistance locus regulates evasion of type I interferon signaling by Chlamydia pneumoniae as a disease tolerance mechanism. PLoS Pathog 9: e1003569 http:\/\/dx.doi.org\/10.1371\/journal.ppat.1003569.","DOI":"10.1371\/journal.ppat.1003569"},{"key":"e_1_3_1_95_2","doi-asserted-by":"crossref","unstructured":"Obreg\u00f3n-Henao A Arnett KA Henao-Tamayo M Massoudi L Creissen E Andries K Lenaerts AJ Ordway DJ. 2015. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. Antimicrob Agents Chemother 59: 6904\u20136912 http:\/\/dx.doi.org\/10.1128\/AAC.00459-15.","DOI":"10.1128\/AAC.00459-15"},{"key":"e_1_3_1_96_2","doi-asserted-by":"crossref","unstructured":"Ordonez AA Tasneen R Pokkali S Xu Z Converse PJ Klunk MH Mollura DJ Nuermberger EL Jain SK. 2016. Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9. Dis Model Mech 9: 779\u2013788 http:\/\/dx.doi.org\/10.1242\/dmm.025643.","DOI":"10.1242\/dmm.025643"},{"key":"e_1_3_1_97_2","doi-asserted-by":"crossref","unstructured":"Lanoix JP Betoudji F Nuermberger E. 2015. Sterilizing activity of pyrazinamide in combination with first-line drugs in a C3HeB\/FeJ mouse model of tuberculosis. Antimicrob Agents Chemother 60: 1091\u20131096 http:\/\/dx.doi.org\/10.1128\/AAC.02637-15.","DOI":"10.1128\/AAC.02637-15"},{"key":"e_1_3_1_98_2","doi-asserted-by":"crossref","unstructured":"Gaonkar S Bharath S Kumar N Balasubramanian V Shandil RK. 2010. Aerosol infection model of tuberculosis in wistar rats. Int J Microbiol 2010: 426035 http:\/\/dx.doi.org\/10.1155\/2010\/426035.","DOI":"10.1155\/2010\/426035"},{"key":"e_1_3_1_99_2","doi-asserted-by":"crossref","unstructured":"Singhal A Aliouat M Herv\u00e9 M Mathys V Kiass M Creusy C Delaire B Tsenova L Fleurisse L Bertout J Camacho L Foo D Tay HC Siew JY Boukhouchi W Romano M Mathema B Dartois V Kaplan G Bifani P. 2011. Experimental tuberculosis in the Wistar rat: a model for protective immunity and control of infection. PLoS One 6: e18632 http:\/\/dx.doi.org\/10.1371\/journal.pone.0018632.","DOI":"10.1371\/journal.pone.0018632"},{"key":"e_1_3_1_100_2","doi-asserted-by":"crossref","unstructured":"Kumar N Vishwas KG Kumar M Reddy J Parab M Manikanth CL Pavithra BS Shandil RK. 2014. Pharmacokinetics and dose response of anti-TB drugs in rat infection model of tuberculosis. Tuberculosis (Edinb) 94: 282\u2013286 http:\/\/dx.doi.org\/10.1016\/j.tube.2014.02.004.","DOI":"10.1016\/j.tube.2014.02.004"},{"key":"e_1_3_1_101_2","doi-asserted-by":"crossref","unstructured":"Chatterji M Shandil R Manjunatha MR Solapure S Ramachandran V Kumar N Saralaya R Panduga V Reddy J Prabhakar KR Sharma S Sadler C Cooper CB Mdluli K Iyer PS Narayanan S Shirude PS. 2014. 1 4-azaindole a potential drug candidate for treatment of tuberculosis. Antimicrob Agents Chemother 58: 5325\u20135331 http:\/\/dx.doi.org\/10.1128\/AAC.03233-14.","DOI":"10.1128\/AAC.03233-14"},{"key":"e_1_3_1_102_2","doi-asserted-by":"crossref","unstructured":"Elwood RL Wilson S Blanco JC Yim K Pletneva L Nikonenko B Samala R Joshi S Hemming VG Trucksis M. 2007. The American cotton rat: a novel model for pulmonary tuberculosis. Tuberculosis (Edinb) 87: 145\u2013154 http:\/\/dx.doi.org\/10.1016\/j.tube.2006.07.001.","DOI":"10.1016\/j.tube.2006.07.001"},{"key":"e_1_3_1_103_2","doi-asserted-by":"crossref","unstructured":"McFarland CT Ly L Jeevan A Yamamoto T Weeks B Izzo A McMurray D. 2010. BCG vaccination in the cotton rat ( Sigmodon hispidus ) infected by the pulmonary route with virulent Mycobacterium tuberculosis . Tuberculosis (Edinb) 90: 262\u2013267 http:\/\/dx.doi.org\/10.1016\/j.tube.2010.03.014.","DOI":"10.1016\/j.tube.2010.03.014"},{"key":"e_1_3_1_104_2","doi-asserted-by":"crossref","unstructured":"Lenaerts AJ Hoff D Aly S Ehlers S Andries K Cantarero L Orme IM Basaraba RJ. 2007. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 51: 3338\u20133345 http:\/\/dx.doi.org\/10.1128\/AAC.00276-07.","DOI":"10.1128\/AAC.00276-07"},{"key":"e_1_3_1_105_2","doi-asserted-by":"crossref","unstructured":"Ahmad Z Fraig MM Pinn ML Tyagi S Nuermberger EL Grosset JH Karakousis PC. 2011. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models. J Antimicrob Chemother 66: 1560\u20131566 http:\/\/dx.doi.org\/10.1093\/jac\/dkr188.","DOI":"10.1093\/jac\/dkr188"},{"key":"e_1_3_1_106_2","doi-asserted-by":"crossref","unstructured":"Ahmad Z Klinkenberg LG Pinn ML Fraig MM Peloquin CA Bishai WR Nuermberger EL Grosset JH Karakousis PC. 2009. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant not drug-resistant Mycobacterium tuberculosis in the guinea pig. J Infect Dis 200: 1136\u20131143 http:\/\/dx.doi.org\/10.1086\/605605.","DOI":"10.1086\/605605"},{"key":"e_1_3_1_107_2","doi-asserted-by":"crossref","unstructured":"Ahmad Z Pinn ML Nuermberger EL Peloquin CA Grosset JH Karakousis PC. 2010. The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters. J Antimicrob Chemother 65: 2172\u20132175 http:\/\/dx.doi.org\/10.1093\/jac\/dkq277.","DOI":"10.1093\/jac\/dkq277"},{"key":"e_1_3_1_108_2","doi-asserted-by":"crossref","unstructured":"Ahmad Z Nuermberger EL Tasneen R Pinn ML Williams KN Peloquin CA Grosset JH Karakousis PC. 2010. Comparison of the \u2018Denver regimen\u2019 against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother 65: 729\u2013734 http:\/\/dx.doi.org\/10.1093\/jac\/dkq007.","DOI":"10.1093\/jac\/dkq007"},{"key":"e_1_3_1_109_2","doi-asserted-by":"crossref","unstructured":"Ahmad Z Fraig MM Bisson GP Nuermberger EL Grosset JH Karakousis PC. 2011. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother 55: 1527\u20131532 http:\/\/dx.doi.org\/10.1128\/AAC.01524-10.","DOI":"10.1128\/AAC.01524-10"},{"key":"e_1_3_1_110_2","doi-asserted-by":"crossref","unstructured":"Dutta NK Alsultan A Gniadek TJ Belchis DA Pinn ML Mdluli KE Nuermberger EL Peloquin CA Karakousis PC. 2013. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother 57: 3910\u20133916 http:\/\/dx.doi.org\/10.1128\/AAC.00761-13.","DOI":"10.1128\/AAC.00761-13"},{"key":"e_1_3_1_111_2","doi-asserted-by":"crossref","unstructured":"Dutta NK Illei PB Peloquin CA Pinn ML Mdluli KE Nuermberger EL Grosset JH Karakousis PC. 2012. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents Chemother 56: 3726\u20133731 http:\/\/dx.doi.org\/10.1128\/AAC.00500-12.","DOI":"10.1128\/AAC.00500-12"},{"key":"e_1_3_1_112_2","doi-asserted-by":"crossref","unstructured":"Shang S Shanley CA Caraway ML Orme EA Henao-Tamayo M Hascall-Dove L Ackart D Lenaerts AJ Basaraba RJ Orme IM Ordway DJ. 2011. Activities of TMC207 rifampin and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother 55: 124\u2013131 http:\/\/dx.doi.org\/10.1128\/AAC.00978-10.","DOI":"10.1128\/AAC.00978-10"},{"key":"e_1_3_1_113_2","doi-asserted-by":"crossref","unstructured":"Dorman SE Goldberg S Stout JE Muzanyi G Johnson JL Weiner M Bozeman L Heilig CM Feng PJ Moro R Narita M Nahid P Ray S Bates E Haile B Nuermberger EL Vernon A Schluger NW Tuberculosis Trials Consortium. 2012. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis 206: 1030\u20131040 http:\/\/dx.doi.org\/10.1093\/infdis\/jis461.","DOI":"10.1093\/infdis\/jis461"},{"key":"e_1_3_1_114_2","unstructured":"Rifat DPB Urbanowski M Luna B Marzinke M Dartois V Savic R Bishai W Dooley K. 2015. Penetration of rifampin and rifapentine into diseased lung in the rabbit cavity pulmonary disease model of TB abstr 8th International Workshop on Clinical Pharmacology of Tuberculosis Drugs San Diego CA."},{"key":"e_1_3_1_115_2","doi-asserted-by":"crossref","unstructured":"Savic RM Weiner M Mac Kenzie WR Engle M Whitworth WC Johnson JL Nsubuga P Nahid P Nguyen NV Peloquin CA Dooley KE Dorman SE Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention. 2017. Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase 2 clinical trials. Clin Pharmacol Ther . [Epub ahead of print.] doi:10.1002\/cpt.634.","DOI":"10.1002\/cpt.634"},{"key":"e_1_3_1_116_2","doi-asserted-by":"crossref","unstructured":"Converse PJ Dannenberg AM Jr Estep JE Sugisaki K Abe Y Schofield BH Pitt ML. 1996. Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli. Infect Immun 64: 4776\u20134787. [PubMed]","DOI":"10.1128\/iai.64.11.4776-4787.1996"},{"key":"e_1_3_1_117_2","doi-asserted-by":"crossref","unstructured":"Manabe YC Dannenberg AM Jr Tyagi SK Hatem CL Yoder M Woolwine SC Zook BC Pitt ML Bishai WR. 2003. Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. Infect Immun 71: 6004\u20136011 http:\/\/dx.doi.org\/10.1128\/IAI.71.10.6004-6011.2003.","DOI":"10.1128\/IAI.71.10.6004-6011.2003"},{"key":"e_1_3_1_118_2","doi-asserted-by":"crossref","unstructured":"Subbian S Tsenova L Yang G O\u2019Brien P Parsons S Peixoto B Taylor L Fallows D Kaplan G. 2011. Chronic pulmonary cavitary tuberculosis in rabbits: a failed host immune response. Open Biol 1: 110016 http:\/\/dx.doi.org\/10.1098\/rsob.110016.","DOI":"10.1098\/rsob.110016"},{"key":"e_1_3_1_119_2","doi-asserted-by":"crossref","unstructured":"Nedeltchev GG Raghunand TR Jassal MS Lun S Cheng QJ Bishai WR. 2009. Extrapulmonary dissemination of Mycobacterium bovis but not Mycobacterium tuberculosis in a bronchoscopic rabbit model of cavitary tuberculosis. Infect Immun 77: 598\u2013603 http:\/\/dx.doi.org\/10.1128\/IAI.01132-08.","DOI":"10.1128\/IAI.01132-08"},{"key":"e_1_3_1_120_2","doi-asserted-by":"crossref","unstructured":"Luna B Kubler A Larsson C Foster B Bagci U Mollura DJ Jain SK Bishai WR. 2015. In vivo prediction of tuberculosis-associated cavity formation in rabbits. J Infect Dis 211: 481\u2013485 http:\/\/dx.doi.org\/10.1093\/infdis\/jiu449.","DOI":"10.1093\/infdis\/jiu449"},{"key":"e_1_3_1_121_2","doi-asserted-by":"crossref","unstructured":"Xu Z Bagci U Kubler A Luna B Jain S Bishai WR Mollura DJ. 2013. Computer-aided detection and quantification of cavitary tuberculosis from CT scans. Med Phys 40: 113701 http:\/\/dx.doi.org\/10.1118\/1.4824979.","DOI":"10.1118\/1.4824979"},{"key":"e_1_3_1_122_2","doi-asserted-by":"crossref","unstructured":"Prideaux B ElNaggar MS Zimmerman M Wiseman JM Li X Dartois V. 2015. Mass spectrometry imaging of levofloxacin distribution in TB-infected pulmonary lesions by MALDI-MSI and continuous liquid microjunction surface sampling. Int J Mass Spectrom 377: 699\u2013708 http:\/\/dx.doi.org\/10.1016\/j.ijms.2014.08.024.","DOI":"10.1016\/j.ijms.2014.08.024"},{"key":"e_1_3_1_123_2","doi-asserted-by":"crossref","unstructured":"Via LE Savic R Weiner DM Zimmerman MD Prideaux B Irwin SM Lyon E O\u2019Brien P Gopal P Eum S Lee M Lanoix JP Dutta NK Shim T Cho JS Kim W Karakousis PC Lenaerts A Nuermberger E Barry CE III Dartois V. 2015. Host-mediated bioactivation of pyrazinamide: implications for efficacy resistance and therapeutic alternatives. ACS Infect Dis 1: 203\u2013214 http:\/\/dx.doi.org\/10.1021\/id500028m.","DOI":"10.1021\/id500028m"},{"key":"e_1_3_1_124_2","doi-asserted-by":"crossref","unstructured":"Prideaux B Dartois V Staab D Weiner DM Goh A Via LE Barry CE III Stoeckli M. 2011. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem 83: 2112\u20132118 http:\/\/dx.doi.org\/10.1021\/ac1029049.","DOI":"10.1021\/ac1029049"},{"key":"e_1_3_1_125_2","doi-asserted-by":"crossref","unstructured":"Carroll MW Jeon D Mountz JM Lee JD Jeong YJ Zia N Lee M Lee J Via LE Lee S Eum SY Lee SJ Goldfeder LC Cai Y Jin B Kim Y Oh T Chen RY Dodd LE Gu W Dartois V Park SK Kim CT Barry CE III Cho SN. 2013. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother 57: 3903\u20133909 http:\/\/dx.doi.org\/10.1128\/AAC.00753-13.","DOI":"10.1128\/AAC.00753-13"},{"key":"e_1_3_1_126_2","doi-asserted-by":"crossref","unstructured":"Via LE Schimel D Weiner DM Dartois V Dayao E Cai Y Yoon YS Dreher MR Kastenmayer RJ Laymon CM Carny JE Flynn JL Herscovitch P Barry CE III. 2012. Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [ 18 F]2-fluoro-deoxy- d -glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother 56: 4391\u20134402 http:\/\/dx.doi.org\/10.1128\/AAC.00531-12.","DOI":"10.1128\/AAC.00531-12"},{"key":"e_1_3_1_127_2","doi-asserted-by":"crossref","unstructured":"Capuano SV III Croix DA Pawar S Zinovik A Myers A Lin PL Bissel S Fuhrman C Klein E Flynn JL. 2003. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 71: 5831\u20135844 http:\/\/dx.doi.org\/10.1128\/IAI.71.10.5831-5844.2003.","DOI":"10.1128\/IAI.71.10.5831-5844.2003"},{"key":"e_1_3_1_128_2","doi-asserted-by":"crossref","unstructured":"Lin PL Rodgers M Smith L Bigbee M Myers A Bigbee C Chiosea I Capuano SV Fuhrman C Klein E Flynn JL. 2009. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 77: 4631\u20134642 http:\/\/dx.doi.org\/10.1128\/IAI.00592-09.","DOI":"10.1128\/IAI.00592-09"},{"key":"e_1_3_1_129_2","doi-asserted-by":"crossref","unstructured":"Lin PL Coleman T Carney JP Lopresti BJ Tomko J Fillmore D Dartois V Scanga C Frye LJ Janssen C Klein E Barry CE III Flynn JL. 2013. Radiologic responses in cynomolgus macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother 57: 4237\u20134244 http:\/\/dx.doi.org\/10.1128\/AAC.00277-13.","DOI":"10.1128\/AAC.00277-13"},{"key":"e_1_3_1_130_2","doi-asserted-by":"crossref","unstructured":"Walsh GP Tan EV dela Cruz EC Abalos RM Villahermosa LG Young LJ Cellona RV Narareno JB Horwitz MA. 1996. The Philippine cynomolgus monkey ( Macaca fasicularis ) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 2: 430\u2013436 http:\/\/dx.doi.org\/10.1038\/nm0496-430.","DOI":"10.1038\/nm0496-430"},{"key":"e_1_3_1_131_2","doi-asserted-by":"crossref","unstructured":"Coleman MT Chen RY Lee M Lin PL Dodd LE Maiello P Via LE Kim Y Marriner G Dartois V Scanga C Janssen C Wang J Klein E Cho SN Barry CE III Flynn JL. 2014. PET\/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med 6: 265ra167 http:\/\/dx.doi.org\/10.1126\/scitranslmed.3009500. [PubMed]","DOI":"10.1126\/scitranslmed.3009500"},{"key":"e_1_3_1_132_2","doi-asserted-by":"crossref","unstructured":"Dietze R Hadad DJ McGee B Molino LP Maciel EL Peloquin CA Johnson DF Debanne SM Eisenach K Boom WH Palaci M Johnson JL. 2008. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 178: 1180\u20131185 http:\/\/dx.doi.org\/10.1164\/rccm.200806-892OC.","DOI":"10.1164\/rccm.200806-892OC"},{"key":"e_1_3_1_133_2","doi-asserted-by":"crossref","unstructured":"Furin JJ Du Bois J van Brakel E Chheng P Venter A Peloquin CA Alsultan A Thiel BA Debanne SM Boom WH Diacon AH Johnson JL. 2016. Early bactericidal activity of AZD5847 in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 60: 6591\u20136599 http:\/\/dx.doi.org\/10.1128\/AAC.01163-16.","DOI":"10.1128\/AAC.01163-16"},{"key":"e_1_3_1_134_2","doi-asserted-by":"crossref","unstructured":"Via LE Weiner DM Schimel D Lin PL Dayao E Tankersley SL Cai Y Coleman MT Tomko J Paripati P Orandle M Kastenmayer RJ Tartakovsky M Rosenthal A Portevin D Eum SY Lahouar S Gagneux S Young DB Flynn JL Barry CE III. 2013. Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset ( Callithrix jacchus ). Infect Immun 81: 2909\u20132919 http:\/\/dx.doi.org\/10.1128\/IAI.00632-13.","DOI":"10.1128\/IAI.00632-13"},{"key":"e_1_3_1_135_2","doi-asserted-by":"crossref","unstructured":"Via LE England K Weiner DM Schimel D Zimmerman MD Dayao E Chen RY Dodd LE Richardson M Robbins KK Cai Y Hammoud D Herscovitch P Dartois V Flynn JL Barry CE III. 2015. A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets. Antimicrob Agents Chemother 59: 4181\u20134189 http:\/\/dx.doi.org\/10.1128\/AAC.00115-15.","DOI":"10.1128\/AAC.00115-15"},{"key":"e_1_3_1_136_2","doi-asserted-by":"crossref","unstructured":"Dye C Glaziou P Floyd K Raviglione M. 2013. Prospects for tuberculosis elimination. Annu Rev Public Health 34: 271\u2013286 http:\/\/dx.doi.org\/10.1146\/annurev-publhealth-031912-114431.","DOI":"10.1146\/annurev-publhealth-031912-114431"},{"key":"e_1_3_1_137_2","doi-asserted-by":"crossref","unstructured":"Barry CE III Boshoff HI Dartois V Dick T Ehrt S Flynn J Schnappinger D Wilkinson RJ Young D. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845\u2013855.","DOI":"10.1038\/nrmicro2236"},{"key":"e_1_3_1_138_2","unstructured":"Lecoeur HF Lagrange PH Truffot-Pernot C Gheorghiu M Grosset J. 1989. Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Clin Exp Immunol 76: 458\u2013462. [PubMed]"},{"key":"e_1_3_1_139_2","doi-asserted-by":"crossref","unstructured":"Nuermberger EL Yoshimatsu T Tyagi S Bishai WR Grosset JH. 2004. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun 72: 1065\u20131071 http:\/\/dx.doi.org\/10.1128\/IAI.72.2.1065-1071.2004.","DOI":"10.1128\/IAI.72.2.1065-1071.2004"},{"key":"e_1_3_1_140_2","doi-asserted-by":"crossref","unstructured":"Lecoeur HF Truffot-Pernot C Grosset JH. 1989. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 140: 1189\u20131193 http:\/\/dx.doi.org\/10.1164\/ajrccm\/140.5.1189.","DOI":"10.1164\/ajrccm\/140.5.1189"},{"key":"e_1_3_1_141_2","doi-asserted-by":"crossref","unstructured":"Gordin F Chaisson RE Matts JP Miller C de Lourdes Garcia M Hafner R Valdespino JL Coberly J Schechter M Klukowicz AJ Barry MA O\u2019Brien RJ. 2000. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 283: 1445\u20131450 http:\/\/dx.doi.org\/10.1001\/jama.283.11.1445.","DOI":"10.1001\/jama.283.11.1445"},{"key":"e_1_3_1_142_2","doi-asserted-by":"crossref","unstructured":"Halsey NA Coberly JS Desormeaux J Losikoff P Atkinson J Moulton LH Contave M Johnson M Davis H Geiter L Johnson E Huebner R Boulos R Chaisson RE. 1998. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 351: 786\u2013792 http:\/\/dx.doi.org\/10.1016\/S0140-6736(97)06532-X.","DOI":"10.1016\/S0140-6736(97)06532-X"},{"key":"e_1_3_1_143_2","unstructured":"Centers for Disease Control and Prevention (CDC) American Thoracic Society. 2003. Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States 2003. MMWR Morb Mortal Wkly Rep 52: 735\u2013739. [PubMed]"},{"key":"e_1_3_1_144_2","doi-asserted-by":"crossref","unstructured":"Nuermberger E Tyagi S Williams KN Rosenthal I Bishai WR Grosset JH. 2005. Rifapentine moxifloxacin or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med 172: 1452\u20131456 http:\/\/dx.doi.org\/10.1164\/rccm.200507-1047OC.","DOI":"10.1164\/rccm.200507-1047OC"},{"key":"e_1_3_1_145_2","doi-asserted-by":"crossref","unstructured":"Sterling TR Scott NA Miro JM Calvet G La Rosa A Infante R Chen MP Benator DA Gordin F Benson CA Chaisson RE Villarino ME Tuberculosis Trials Consortium the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259). 2016. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS 30: 1607\u20131615 http:\/\/dx.doi.org\/10.1097\/QAD.0000000000001098.","DOI":"10.1097\/QAD.0000000000001098"},{"key":"e_1_3_1_146_2","doi-asserted-by":"crossref","unstructured":"Zhang T Zhang M Rosenthal IM Grosset JH Nuermberger EL. 2009. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 180: 1151\u20131157 http:\/\/dx.doi.org\/10.1164\/rccm.200905-0795OC.","DOI":"10.1164\/rccm.200905-0795OC"},{"key":"e_1_3_1_147_2","doi-asserted-by":"crossref","unstructured":"Zhang T Li SY Williams KN Andries K Nuermberger EL. 2011. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med 184: 732\u2013737 http:\/\/dx.doi.org\/10.1164\/rccm.201103-0397OC.","DOI":"10.1164\/rccm.201103-0397OC"},{"key":"e_1_3_1_148_2","doi-asserted-by":"crossref","unstructured":"Lanoix JP Betoudji F Nuermberger E. 2014. Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 58: 2316\u20132321 http:\/\/dx.doi.org\/10.1128\/AAC.02658-13.","DOI":"10.1128\/AAC.02658-13"},{"key":"e_1_3_1_149_2","doi-asserted-by":"crossref","unstructured":"Dutta NK Illei PB Jain SK Karakousis PC. 2014. Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice. Am J Pathol 184: 2045\u20132055 http:\/\/dx.doi.org\/10.1016\/j.ajpath.2014.03.008.","DOI":"10.1016\/j.ajpath.2014.03.008"},{"key":"e_1_3_1_150_2","doi-asserted-by":"crossref","unstructured":"Subbian S Tsenova L O\u2019Brien P Yang G Kushner NL Parsons S Peixoto B Fallows D Kaplan G. 2012. Spontaneous latency in a rabbit model of pulmonary tuberculosis. Am J Pathol 181: 1711\u20131724 http:\/\/dx.doi.org\/10.1016\/j.ajpath.2012.07.019.","DOI":"10.1016\/j.ajpath.2012.07.019"},{"key":"e_1_3_1_151_2","doi-asserted-by":"crossref","unstructured":"Cynamon MH Zhang Y Harpster T Cheng S DeStefano MS. 1999. High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection. Antimicrob Agents Chemother 43: 2922\u20132924. [PubMed]","DOI":"10.1128\/AAC.43.12.2922"},{"key":"e_1_3_1_152_2","doi-asserted-by":"crossref","unstructured":"Almeida D Nuermberger E Tasneen R Rosenthal I Tyagi S Williams K Peloquin C Grosset J. 2009. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 53: 4178\u20134184 http:\/\/dx.doi.org\/10.1128\/AAC.00830-09.","DOI":"10.1128\/AAC.00830-09"},{"key":"e_1_3_1_153_2","doi-asserted-by":"crossref","unstructured":"de Steenwinkel JE Aarnoutse RE de Knegt GJ ten Kate MT Teulen M Verbrugh HA Boeree MJ van Soolingen D Bakker-Woudenberg IA. 2013. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. Am J Respir Crit Care Med 187: 1127\u20131134 http:\/\/dx.doi.org\/10.1164\/rccm.201207-1210OC.","DOI":"10.1164\/rccm.201207-1210OC"},{"key":"e_1_3_1_154_2","doi-asserted-by":"crossref","unstructured":"Rosenthal IM Tasneen R Peloquin CA Zhang M Almeida D Mdluli KE Karakousis PC Grosset JH Nuermberger EL. 2012. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 56: 4331\u20134340 http:\/\/dx.doi.org\/10.1128\/AAC.00912-12.","DOI":"10.1128\/AAC.00912-12"},{"key":"e_1_3_1_155_2","doi-asserted-by":"crossref","unstructured":"Lenaerts AM Chase SE Chmielewski AJ Cynamon MH. 1999. Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. Antimicrob Agents Chemother 43: 2356\u20132360. [PubMed]","DOI":"10.1128\/AAC.43.10.2356"},{"key":"e_1_3_1_156_2","doi-asserted-by":"crossref","unstructured":"Rosenthal IM Zhang M Williams KN Peloquin CA Tyagi S Vernon AA Bishai WR Chaisson RE Grosset JH Nuermberger EL. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4: e344 http:\/\/dx.doi.org\/10.1371\/journal.pmed.0040344.","DOI":"10.1371\/journal.pmed.0040344"},{"key":"e_1_3_1_157_2","doi-asserted-by":"crossref","unstructured":"Rosenthal IM Zhang M Almeida D Grosset JH Nuermberger EL. 2008. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 178: 989\u2013993 http:\/\/dx.doi.org\/10.1164\/rccm.200807-1029OC.","DOI":"10.1164\/rccm.200807-1029OC"},{"key":"e_1_3_1_158_2","doi-asserted-by":"crossref","unstructured":"Li SY Irwin SM Converse PJ Mdluli KE Lenaerts AJ Nuermberger EL. 2015. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob Agents Chemother 59: 4026\u20134030 http:\/\/dx.doi.org\/10.1128\/AAC.00105-15.","DOI":"10.1128\/AAC.00105-15"},{"key":"e_1_3_1_159_2","doi-asserted-by":"crossref","unstructured":"De Groote MA Gilliland JC Wells CL Brooks EJ Woolhiser LK Gruppo V Peloquin CA Orme IM Lenaerts AJ. 2011. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis . Antimicrob Agents Chemother 55: 1237\u20131247 http:\/\/dx.doi.org\/10.1128\/AAC.00595-10.","DOI":"10.1128\/AAC.00595-10"},{"key":"e_1_3_1_160_2","doi-asserted-by":"crossref","unstructured":"Fillion A Aubry A Brossier F Chauffour A Jarlier V Veziris N. 2013. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. Antimicrob Agents Chemother 57: 4496\u20134500 http:\/\/dx.doi.org\/10.1128\/AAC.00506-13.","DOI":"10.1128\/AAC.00506-13"},{"key":"e_1_3_1_161_2","doi-asserted-by":"crossref","unstructured":"Poissy J Aubry A Fernandez C Lott MC Chauffour A Jarlier V Farinotti R Veziris N. 2010. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 54: 4765\u20134771 http:\/\/dx.doi.org\/10.1128\/AAC.00968-10.","DOI":"10.1128\/AAC.00968-10"},{"key":"e_1_3_1_162_2","doi-asserted-by":"crossref","unstructured":"Veziris N Truffot-Pernot C Aubry A Jarlier V Lounis N. 2003. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosisin vivo . Antimicrob Agents Chemother 47: 3117\u20133122 http:\/\/dx.doi.org\/10.1128\/AAC.47.10.3117-3122.2003.","DOI":"10.1128\/AAC.47.10.3117-3122.2003"},{"key":"e_1_3_1_163_2","doi-asserted-by":"crossref","unstructured":"Ahmad Z Tyagi S Minkowski A Peloquin CA Grosset JH Nuermberger EL. 2013. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med 188: 97\u2013102 http:\/\/dx.doi.org\/10.1164\/rccm.201212-2328OC.","DOI":"10.1164\/rccm.201212-2328OC"},{"key":"e_1_3_1_164_2","doi-asserted-by":"crossref","unstructured":"Ji B Lounis N Truffot-Pernot C Grosset J. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis . Antimicrob Agents Chemother 39: 1341\u20131344 http:\/\/dx.doi.org\/10.1128\/AAC.39.6.1341.","DOI":"10.1128\/AAC.39.6.1341"},{"key":"e_1_3_1_165_2","doi-asserted-by":"crossref","unstructured":"Grosset JH Tyagi S Almeida DV Converse PJ Li SY Ammerman NC Bishai WR Enarson D Tr\u00e9bucq A. 2013. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 188: 608\u2013612 http:\/\/dx.doi.org\/10.1164\/rccm.201304-0753OC. [PubMed]","DOI":"10.1164\/rccm.201304-0753OC"},{"key":"e_1_3_1_166_2","doi-asserted-by":"crossref","unstructured":"Williams KN Stover CK Zhu T Tasneen R Tyagi S Grosset JH Nuermberger E. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 53: 1314\u20131319 http:\/\/dx.doi.org\/10.1128\/AAC.01182-08.","DOI":"10.1128\/AAC.01182-08"},{"key":"e_1_3_1_167_2","unstructured":"American Thoracic Society Centers for Disease Control. 2000. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recommend Rep 49 (RR-6) : 1\u201351."},{"key":"e_1_3_1_168_2","unstructured":"Centers for Disease Control and Prevention (CDC). 2011. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 60: 1650\u20131653. [PubMed]"},{"key":"e_1_3_1_169_2","unstructured":"World Health Organization. 2015. Guidelines on the Management of Latent Tuberculosis Infection . World Health Organization Geneva Switzerland."},{"key":"e_1_3_1_170_2","unstructured":"Blumberg H. 2016. Rifpentine plus isoniazid eradicates Mycobacterium tuberculosis among rhesus macaques with latent TB infection. Abstr 9th International Workshop on Clinical Pharmacology of Tuberculosis Drugs Liverpool UK 24 October 2016."}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/microbiolspec.TBTB2-0034-2017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/microbiolspec.TBTB2-0034-2017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:17:17Z","timestamp":1659140237000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/microbiolspec.TBTB2-0034-2017"}},"subtitle":[],"editor":[{"given":"William R.","family":"Jacobs Jr.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Helen","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Valerie","family":"Mizrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Ian M.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,19]]},"references-count":169,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5,19]]}},"alternative-id":["10.1128\/microbiolspec.TBTB2-0034-2017"],"URL":"https:\/\/doi.org\/10.1128\/microbiolspec.tbtb2-0034-2017","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,19]]},"assertion":[{"value":"2017-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"5.3.24"}}